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ATIC, SHMT2, and SLC46A1 have essential roles in one-carbon (1-C) transfer. The authors
examinedwhether associations between ovarian carcinoma and 15 variants in these genes
are modiﬁed by regular multivitamin use, a source of 1-C donors, among Caucasian
participants from two US case–control studies. Using a phased study design, variant-
by-multivitamin interactions were tested, and associations between variants and ovarian
carcinoma were reported stratiﬁed by multivitamin supplement use. Per-allele risk associa-
tions were modiﬁed by multivitamin use at six variants among 655 cases and 920 controls
(Phase 1). In a larger sample of 968 cases and 1,265 controls (Phases 1 and 2), interactions
were signiﬁcant (P ≤ 0.03) for two variants, particularly among regular multivitamin users:
ATIC rs7586969 [odds ratio (OR)= 0.7, 95% conﬁdence interval (CI)= 0.6–0.9] and ATIC
rs16853834 (OR= 1.5, 95% CI= 1.1–2.0). The two ATIC single nucleotide polymorphisms
(SNPs) did not share the samehaplotype; however, the haplotypes they comprisedmirrored
their SNP risk associations among regular multivitamin supplement users. A multi-variant
analysis was also performed by comparing the observed likelihood ratio test statistic from
adjusted models with and without the two ATIC variant-by-multivitamin interaction terms
with a null distribution of test statistics generated by permuting case status 10,000 times.
The corresponding observed P value of 0.001 was more extreme than the permutation-
derived P value of 0.009, suggesting rejection of the null hypothesis of no association. In
summary, there is little statistical evidence that the 15 variants are independently associ-
ated with risk of ovarian carcinoma. However, the statistical interaction of ATIC variants
with regular multivitamin intake, when evaluated at both the SNP and gene level, may
support these ﬁndings as relevant to ovarian health and disease processes.
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INTRODUCTION
The one-carbon (1-C) transfer pathway refers to biologic reac-
tions that depend on 1-C transfers mediated by folate coenzymes:
these transfers play essential roles inmanymajor cellular processes
including nucleic acid biosynthesis and methyl group generation
(Ulrich et al., 2008). Consequently, perturbations in this pathway
caused by folate or 1-C donor nutrient deﬁciency can compromise
DNA synthesis and methylation and can lead to tumorigenesis
(Choi and Mason, 2000). Polymorphisms in genes involved in
the 1-C transfer pathway may mimic folate or 1-C donor deﬁ-
ciency and inﬂuence the risk of cancers. However, risk may be
modiﬁed by dietary factors such as folate and other 1-C donor
nutrients (Ma et al., 1997, 2009; Maruti et al., 2009; Levine et al.,
2010).
We previously examined the association between single
nucleotide polymorphisms (SNPs) in several genes in the 1-C
transfer pathway and ovarian carcinoma risk, but found little
evidence in secondary analyses for interactions with regularmulti-
vitamin supplement use as a source of folate and other B-vitamins
(Kelemen et al., 2008). In that study, the smallest false positive
report probabilities (FPRP) for interaction analyses were between
0.54 and 0.66 for associations between three SNPs in DNMT3A
and risk of ovarian carcinoma among multivitamin supplement
users (Kelemen et al., 2008).
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In the present study,we elucidated the potential contribution of
variants in three genes for which we hypothesized, a priori, would
have interactive effects with multivitamin supplement use as a
source of folate and other 1-C donor nutrients. Aminoimidazole
carboxamide ribonucleotide transformylase/inosine monophos-
phate cyclohydrolase (ATIC) is a single bifunctional protein that
catalyzes the penultimate and ﬁnal steps of the de novo purine
biosynthesis via a 1-C transfer from reduced folate (Wolan et al.,
2004). The ATIC gene is highly conserved across several species
from Escherichia coli to humans (Cheong et al., 2004). Serine
hydroxymethyltransferase 2 (SHMT2) is the mitochondrial isoen-
zyme of cytoplasmic SHMT1.Both enzymes catalyze the reversible
transfer of a single carbon from serine to tetrahydrofolate to form
glycine and 5,10 methylene-tetrahydrofolate, which is required for
de novo pyrimidine synthesis (Tibbetts and Appling, 2010). Poly-
morphisms in SHMT1 have been reported to alter the risk of ovar-
ian carcinoma (Kelemen et al., 2008), squamous cell carcinoma
of the head and neck (Zhang et al., 2005), and lung carcinoma
(Wang et al., 2007). Solute carrier protein 46A1 (SLC46A1) plays
a critical role in the absorption of folate from diet by function-
ing as a proton-coupled folate transporter and as a mediator of
folate receptor endocytosis (Qiu et al., 2006; Zhao et al., 2009).
Nucleotide substitutions in SLC46A1 that result in pointmutations
or a splice variant in the corresponding protein have recently been
described in patients exhibiting hereditary folate malabsorption
(Zhao et al., 2007).
We present here our ﬁndings for the associations between 15
common SNPs in ATIC, SHMT2, and SLC46A1 and ovarian car-
cinoma risk, stratiﬁed by regular multivitamin supplement use as
an estimate of B-vitamin intake, using data from two case–control
studies including 968 cases and 1,265 controls.
MATERIALS AND METHODS
STUDY POPULATION
The study population consisted of a combination of two individ-
ual studies of epithelial ovarian cancer fromMayoClinic andDuke
University. Details of the study protocols have been published
previously (Sellers et al., 2005). Brieﬂy, participants included Cau-
casians and African-Americans enrolled from June 1999 onward.
MayoClinic caseswere 20 years of age or older and resident in a six-
state region (Minnesota, Iowa, Wisconsin, Illinois, North Dakota,
and South Dakota) that deﬁned the primary catchment area. Con-
trols were women seeking general medical care at Mayo Clinic.
Duke University cases were between 20 and 74 years of age and
identiﬁed from a 48-county region in North Carolina. Controls
were identiﬁed from the same region using population-based list-
assisted random digit dialing. In both studies, cases were newly
diagnosed, histologically conﬁrmed, of either borderline or inva-
sive behavior, and enrolled within 1 year of diagnosis. Controls
had at least one intact ovary, no history of ovarian cancer and were
frequency-matched to cases on age (5-year age categories), race,
and state of residence. The response among cases and controls,
respectively, was high at Mayo Clinic (83 and 74%) and Duke Uni-
versity (75 and 64%). All participants provided written informed
consent and procedures followed were in accordance with the
Institutional Review Board of Mayo Clinic and the Institutional
Review Board of Duke University Medical Center.
ASSESSMENT OF REGULAR MULTIVITAMIN SUPPLEMENT USE AND
OTHER RISK FACTORS
Multivitamin supplement use and information on established risk
factors such as reproductive history, family history of cancer,med-
ical history, and lifestyle habits were obtained from all subjects
through in-person interviews using study-speciﬁc questionnaires.
Variables were harmonized across studies for this analysis. The
Mayo Clinic study began collecting information on multivitamin
intake 3 years after the start of the study,while the Duke University
study elicited this information from the start of the study. At Duke
University, participants indicated their regularity of multivitamin
use (none, <1 pill per week, 1–2 per week, 3–4 per week, 5–6
per week, or daily) during the previous 5 years. We deﬁned users
as those who consumed at least three pills per week for at least
48months during the past 5 years (e.g., allowing 80% adherence).
At Mayo Clinic, participants responded yes or no to whether they
consumed multivitamins at least four times per week during the
previous year for controls and 1 year before diagnosis for cases;
they also estimated their total number of years’ duration of use. To
create a “multivitamin user”deﬁnition that compared to the Duke
University subjects, we deﬁned Mayo Clinic users as women con-
suming at least four pills per week for at least 48months’ duration
of lifetime use.
GENETIC ANALYSIS
DNA was obtained from peripheral blood samples using salt
extraction protocols (Sellers et al., 2005; Cunningham et al., 2008).
In addition,whole genome ampliﬁcation (WGA)using theREPLI-
G WGA protocol (Qiagen Inc., Valencia, CA, USA) was used to
enrich DNA samples from Duke University due to limited quan-
tities. Excellent (>99%) concordance between genomic and WGA
DNAgenotype calls for these samples has been reported previously
(Cunningham et al., 2008).
TagSNPs were chosen using SNP information from unrelated
Caucasian samples within HapMap Consortium’s release 22 (The
International HapMapConsortium, 2003) as previously described
(Kelemen et al., 2008), and also for their predicted likelihood of
successful genotyping using the Illumina Golden GateAssay™.We
selected nine tagSNPs in ATIC (rs3772078, rs2372536, rs1880586,
rs1983462, rs16853826, rs7586969, rs16853834, rs1404772, and
rs7604984) from among 45 individual SNPs, two tagSNPs in
SHMT2 (rs7301155 and rs2229716) from among two individ-
ual SNPs and four tagSNPs in SLC46A1 (rs9894260, rs739439,
rs2239908, and rs17719944) fromamong 10 individual SNPs using
criteria of minor allele frequency (MAF)≥ 0.05 and pairwise link-
age disequilibrium(LD)of r2< 0.8. The SNPswere locatedwithin,
and 5 kb upstream and downstream of, each gene region.
The 15 tagSNPs were genotyped using a phased study design.
In the ﬁrst phase (Phase 1), we genotyped the SNPs as part of
a larger investigation of 1,152 SNPs in a variety of pathways
using the Illumina GoldenGate™assay and Illumina BeadStudio
software (Oliphant et al., 2002; Fan et al., 2005; Steemers and
Gunderson, 2005). Genotyping was attempted on 897 genomic
DNA samples from Mayo Clinic and 1,279 WGA samples from
Duke University (total= 2,176 including 129 duplicate samples)
for subjects recruited through March 2006 as well as 65 labora-
tory controls. Of these samples, we excluded 44 (one Mayo Clinic
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sample and 43 Duke University samples) with call rates< 90%
and Illumina quality control (GenCall) scores< 0.25, and 22 sam-
ples where the cancer was not of epithelial origin or the samples
were mislabeled, resulting in 1,981 unique samples that were suc-
cessfully genotyped. The sample call rate was 99.74% and the
concordance for duplicate samples was 99.99%. All 15 tagSNPs in
ATIC, SHMT2, and SLC46A1 were genotyped successfully, except
SHMT2 rs7301155 that failed inDukeUniversity samples. InPhase
2, we genotyped or imputed the 15 tagSNPs as part of a genome-
wide association study (GWAS) of ovarian carcinoma using the
Illumina 610K chip on 186 genomic DNA samples from Mayo
Clinic and 477 WGA samples from Duke University for sub-
jects recruited after March 2006. Genotyping call rates for these
SNPs were≥ 99%. Imputation was performed using the MACH
software (Li et al., 2009) and the phase II HapMap (release 22)
referent genotypes for Caucasian samples for eight SNPs [ATIC
(rs2372536, rs1880586, rs1983462, rs16853826, and rs7586969),
SHMT2 (rs7301155 and rs2229716), and SLC46A1 (rs9894260)].
BecauseSHMT2 rs7301155 failed inDukeUniversity samples from
Phase 1, we included the imputed genotypes for this SNP from
both Phase 1 and Phase 2 Duke University samples represented on
the GWAS. Squared correlations between imputed and true geno-
types were between 0.93 and 0.99, except r2 = 0.43 for SHMT2
rs2229716, which was likely due to its rare frequency (Table A1 in
Appendix).
STATISTICAL ANALYSIS
Analyses were restricted to subjects who were self-reported Cau-
casian controls or cases with invasive epithelial ovarian carcinoma,
resulting in a ﬁnal sample size of 1,575 participants in Phase 1
from Mayo Clinic (312 cases and 439 controls) and Duke Univer-
sity (343 cases and 481 controls) and 658 participants in Phase
2 from Mayo Clinic (89 cases and 96 controls) and Duke Uni-
versity (224 cases and 249 controls). Genotypes of participants
were used to estimate allele frequencies and chi squared tests were
used to examine deviations of genotype frequencies from those
expected under Hardy–Weinberg equilibrium (HWE) in control
subjects. Pairwise LD was examined across all SNPs with the r2
statistic using Haploview (Barrett et al., 2005). Data from Mayo
Clinic and Duke University were combined following conﬁrma-
tion of no statistical heterogeneity in SNP associations between
study sites.
Our primary hypothesis was that SNP associations would be
modiﬁed by regular multivitamin supplement use as a source of
folate or other nutrients involved 1-C transfer. We evaluated this
ﬁrst in Phase 1 samples. Interactions were evaluated with theWald
test inmodels that included a one degree-of-freedomproduct term
for regular multivitamin supplement use (yes/no) and the ordi-
nal coding for genotype, in addition to the covariates age (<40,
40–49, 50–59, 60–69, and 70+ years), region of residence (Min-
nesota, Iowa, Wisconsin, Illinois, North Dakota, South Dakota,
and North Carolina), SNP, regular multivitamin supplement use,
body mass index, age at menarche, oral contraceptive use, post-
menopausal status, postmenopausal hormone use, parity/age at
ﬁrst birth, smoking, and education (see Table 2 for categories).
To determine the degree of falsely positive ﬁndings due to the
number of interaction tests that were performed, we calculated
q-values to estimate false discovery rates (FDR; Hochberg and
Benjamini, 1990). Associations between SNPs and ovarian car-
cinoma were stratiﬁed by regular multivitamin supplement use
and estimated as odds ratios (OR) with 95% conﬁdence intervals
(CI) using multivariable-adjusted unconditional logistic regres-
sion under ordinal genetic models. For SNPs where the tests for
interaction had higher FDR q-values (e.g., >0.23 in our data),
suggesting a higher likelihood of falsely positive tests, we esti-
mated associations between the genetic main effects and ovarian
carcinoma under both co-dominant and ordinal genetic models.
Models evaluating the main effects of SNPs were adjusted for age
and region of residence. Adjustment for additional covariates did
not change the ORs (data not shown).
We performed the same analyses using Phase 2 samples as an
independent replication,and then combined thePhase 1 andPhase
2 samples to increase statistical power. To account for the poten-
tial correlations among SNPs within genes, we performed both a
multi-variant analysis and haplotype analysis. The multi-variant
analysis was performed by calculating a likelihood ratio test (LRT)
statistic comparing a regression model consisting of the main
effects of those SNPs exhibiting signiﬁcant interactions with mul-
tivitamin supplement use, their corresponding interaction terms,
and potential confounding variables to a model without the SNP-
by-multivitamin interaction terms. SNP main effects and their
interaction terms were regressed under the ordinal (log-additive)
geneticmodel. Permutation-based testswere thenused to compute
P values from a null distribution of the LRT statistic generated by
permuting case status 10,000 times. The corresponding P value
threshold was calculated as the probability of observing a per-
muted LRT statistic as extreme or more extreme than the observed
LRT statistic. We also estimated haplotype frequencies for each
gene, stratiﬁed and unstratiﬁed by regular multivitamin supple-
ment use, by computing the posterior probabilities of all possible
haplotypes for an individual, conditioned on the observed geno-
types,using an expectation–maximization algorithm(Schaid et al.,
2002). We used these probabilities to deﬁne haplotype design
variables that estimated the number of each of the haplotypes
carried by an individual, and retained only those with estimated
frequencies of>1%.We ﬁrst tested whether differences among the
haplotypeswithin each genewere associated statisticallywith ovar-
ian carcinoma overall (P < 0.016, Bonferroni-corrected for three
genes). Next, associations between individual haplotypes and risk
were estimated under ordinal genetic models (e.g., carriage of 0,
1, or 2 copies of a particular haplotype; Schaid, 2011). Individ-
ual associations were not considered statistically signiﬁcant in the
absence of global signiﬁcance.
Statistical tests were two-sided, and were implemented with
SAS (SAS Institute, NC), R (R Development Core Team, 2011),
and Haplo.stats (Schaid, 2011) software.
RESULTS
There was no evidence of deviation from HWE in controls from
both studies for anyof the SNPs. TheMAFs among controls ranged
from 0.04 to 0.48 and were similar across study sites in Phase 1
(Table A1 in Appendix), Phase 2 (data not shown), and Phases
1 and 2 combined, with imputed SNPs in Phases 1 and 2 com-
bined showing similar MAFs as typed SNPs in Phase 1 (Table A1
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in Appendix). The distribution of some covariates varied among
cases and controls at both Mayo Clinic and Duke University in
Phase 1 (Table A2 in Appendix), Phase 2 (data not shown), and
Phases 1 and 2 combined (Table 1); however, histological subtypes
of tumors were distributed comparably for both studies.
In Phase 1, the associations between six SNPs and ovarian carci-
noma risk were modiﬁed by regular multivitamin supplement use
at the smallest FDR q-value of 0.23: ATIC rs16853826, rs7586969
and rs16853834, SHMT2 rs7301155, and SLC46A1 rs9894260 and
rs739439 (Table 2). In stratiﬁed analyses, among women who took
multivitamins regularly, the strongest associations were observed
between ovarian carcinoma and ATIC rs16853834 (OR= 1.5,
95% CI= 1.1–2.1, P = 0.01) and SHMT2 rs7301155 (OR= 1.7,
95% CI= 1.1–2.6, P = 0.01). Among non-regular supplement
users, a trend was observed between ovarian carcinoma and ATIC
rs16853826 (OR= 0.7, 95% CI= 0.5–1.0, P = 0.06). Comparable
stratiﬁed analyses are shown in Table A3 in Appendix for Phase 2
samples, with none of the aforementioned SNPs showing statisti-
cally signiﬁcant interactions in this smaller sample, although the
direction of association among multivitamin supplement users
was consistent for ATIC rs16853834 (OR= 1.6, 95% CI= 0.7–
3.7). Combining Phase 1 and Phase 2 samples (968 cases and
1,265 controls; Table 3), statistically signiﬁcant interactions were
observed between regular multivitamin supplement use and ATIC
rs7586969 (OR= 0.7, 95% CI= 0.6–0.9) and ATIC rs16853834
(OR= 1.5, 95% CI= 1.1–2.0).
A multi-variant analysis was performed by calculating a
LRT statistic comparing adjusted models that included ATIC
rs7586969 and ATIC rs16853834, multivitamin use and the SNP-
by-multivitamin interaction terms to a model without ATIC SNP-
by-multivitamin interaction terms, and comparing this to a null
distribution of the LRT statistic generated by permuting case sta-
tus 10,000 times. The observed P value for ATIC (χ2 = 12.98, 2
df, P = 0.001) was more extreme than the P value derived from
permutation testing (P = 0.009), suggesting the evidence is incon-
sistent with the null hypothesis of no association between ATIC
SNP-by-multivitamin interactions and risk of ovarian carcinoma.
In haplotype analyses, only the ATIC gene was statistically sig-
niﬁcantly associatedwith ovarian carcinoma among regularmulti-
vitamin supplement users (Table 4: global haplotype test P = 0.01;
data not shown for SHMT2 and SLC46A1). The two ATIC SNPs,
rs7586969, and rs16853834, whose minor alleles showed opposing
risks, did not share the same haplotype; however, the haplotypes
they comprised mirrored their SNP risk associations among reg-
ular multivitamin supplement users. Haplotype #1 accounted for
24% of all estimated haplotypes, comprised the minor allele of
ATIC rs7586969 and was associated with a 24% decreased risk.
Haplotype #9 accounted for 13%of all estimated haplotypes, com-
prised the minor allele of ATIC rs16853834 and was associated
with a 39% increased risk. A third haplotype, haplotype #10, with
8% frequency, comprised common alleles forATIC rs7586969 and
rs16853834 and was associated with a 42% increased risk. Among
non-users, haplotype #5 was associated with a 27% decreased risk,
but the global haplotype test was not statistically signiﬁcant. None
of the associations were statistically signiﬁcant in the unstratiﬁed
data. Squared correlations among the SNPs are shown inFigureA1
in Appendix.
For remaining SNPs with FDR q-values> 0.23 in Phase 1,
we estimated main effect associations with ovarian carcinoma
(Table A4 in Appendix). An increased risk was observed among 12
carriers homozygous for the rare variant SLC46A1 rs9894260 com-
pared to carriers homozygous for the wildtype allele (OR= 5.4,
95% CI= 1.4–20.5). Similar results were seen using Phase 2 sam-
ples (data not shown), as well as Phase 1 and Phase 2 samples
combined (Table A5 in Appendix). The main effect association
between regular multivitamin supplement use and ovarian car-
cinoma in Phase 1 and Phase 2 samples combined was not sta-
tistically signiﬁcant at P < 0.05 (multivariable OR= 0.86, 95%
CI= 0.70–1.06, P = 0.15; data not shown).
DISCUSSION
We evaluated the association between 15 SNPs in ATIC, SHMT2,
and SLC46A1 in the 1-C transfer pathway and ovarian carcinoma
risk, and the modiﬁcation of risk by regular multivitamin sup-
plement use among 968 cases and 1,265 controls. There was little
statistical evidence that SNPs or haplotypes in these genes were
independently associated with ovarian carcinoma risk. However,
the associations of ATIC rs7586969 and ATIC rs16853834 with
ovarian carcinoma, when stratiﬁed by regular multivitamin sup-
plement use and evaluated further in multi-variant and haplotype
analyses, suggest the potentially important role that lifestyle factors
may have in modifying genetic susceptibility.
We calculated that six interactions between SNPs and reg-
ular multivitamin use had an FDR q-value of 0.23 indicating
that, out of 100 SNPs with this FDR q-value, 23 will be falsely
positive, or approximately one in four. Further analyses in a
larger sample showed consistent associations for two of these
SNPs at P < 0.05. ATIC rs7586969 and ATIC rs16853834 have
MAF in our data of 0.39 and 0.16, respectively, but are weakly
correlated with each other (pairwise LD r2 = 0.12). The power
to detect these associations was relatively high: with an average
exposure in our control group of 43% for regular multivita-
min supplement use, we achieved close to 80% power needed
with 1,054 cases using a ratio of 1:1.3 case–control pairs (actual:
968 cases and 1,265 controls) to detect an OR of 0.7 (ATIC
rs7586969) at alpha= 0.05, and we would require 1,161 case–
control pairs to detect an OR of 1.5 (ATIC rs16853834) under
the log-additive genetic model (Quanto version 1.2, CA, USA,
http://hydra.usc.edu/gxe). The power to detect the haplotype asso-
ciations,where the greatest frequencywas 24% (haplotype #1),was
lower. The presence of two SNPs in the same gene with relatively
independent (and opposing) effects was resolved with haplotype
analysis: the two SNPs do not share the same haplotype. Both
the haplotype analysis and the multi-variant, permutation-based
test suggest the data are inconsistent with the null hypothesis of
no association between ATIC SNP-by-multivitamin interactions
and risk of ovarian carcinoma. The aforementioned ATIC SNPs
are intronic and, unlike exons, little is known of their role in
the regulation of the ﬁnal functional protein. However, because
we genotyped tagSNPs, which merely identify a region in the
gene at which an association is found, additional genotyping
of the region (ﬁnemapping) and association testing is required
to determine the precise causal variant(s). In vitro cell culture
studies, where the nutrient medium can be manipulated, could
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Table 1 | Characteristics of 2,233 Caucasian subjects (Phases 1 and 2), Mayo Clinic, and Duke University.
Mayo Clinic Duke University
Cases (n=401) Controls (n=535) Cases (n=567) Controls (n=730)
Age, year [mean (SD)] 61.0 (12.5) 60.7 (13.2) 57.3 (10.3) 55.3 (12.0)
BODY MASS INDEX, kg/m2
<23 [n (%)] 80 (20.5) 127 (24.8) 152 (27.6) 203 (28.4)
23–26 [n (%)] 100 (25.6) 150 (29.3) 131 (23.8) 173 (24.2)
26–29 [n (%)] 75 (19.2) 99 (19.3) 113 (20.5) 141 (19.7)
≥29 [n (%)] 136 (34.8) 136 (26.6) 155 (28.1) 199 (27.8)
AGEAT MENARCHE, year
<12 [n (%)] 63 (19.0) 77 (15.3) 139 (24.7) 132 (18.1)
12 [n (%)] 84 (25.3) 111 (22.0) 160 (28.4) 210 (28.8)
13 [n (%)] 93 (28.0) 149 (29.5) 139 (24.7) 206 (28.3)
≥14 [n (%)] 92 (27.7) 168 (33.3) 126 (22.3) 181 (24.8)
ORAL CONTRACEPTIVE USE, months
Never [n (%)] 182 (47.5) 200 (39.8) 194 (40.3) 207 (31.1)
1–48 [n (%)] 101 (26.4) 107 (21.3) 142 (29.5) 181 (27.2)
≥48 [n (%)] 100 (26.1) 196 (39.0) 145 (30.2) 278 (41.7)
POSTMENOPAUSAL STATUS
Yes [n (%)] 290 (74.7) 393 (76.0) 251 (46.9) 502 (69.8)
POSTMENOPAUSAL HORMONE USE, months
Never [n (%)] 241 (61.6) 287 (58.5) 211 (39.2) 407 (58.4)
1–60 [n (%)] 71 (18.2) 91 (18.5) 166 (30.9) 147 (21.1)
≥60 [n (%)] 79 (20.2) 113 (23.0) 161 (29.9) 143 (20.5)
PARITY, n/age at first birth, year
Nulliparous [n (%)] 69 (17.4) 77 (15.0) 113 (19.9) 94 (12.9)
1–2/≤20 [n (%)] 29 (7.3) 26 (5.1) 80 (14.1) 92 (12.6)
1–2/≥20 [n (%)] 115 (29.0) 155 (30.1) 208 (36.7) 314 (43.0)
≥3/≤20 [n (%)] 77 (19.4) 74 (14.4) 80 (14.1) 92 (12.6)
≥3/≥20 [n (%)] 106 (26.8) 183 (35.5) 86 (15.2) 138 (18.9)
FAMILY HISTORY OF OVARIAN CANCERa
Yes [n (%)] 50 (12.6) 42 (8.1) 56 (9.9) 46 (6.3)
SMOKING, pack-years
None [n (%)] 242 (63.7) 333 (68.5) 303 (55.7) 376 (53.5)
≤20 [n (%)] 75 (19.7) 100 (20.6) 137 (25.2) 187 (26.6)
>20 [n (%)] 63 (16.6) 53 (10.9) 104 (19.1) 140 (19.9)
EDUCATION
No diploma [n (%)] 22 (5.8) 21 (4.1) 49 (8.6) 66 (9.0)
High School diploma [n (%)] 136 (35.9) 133 (25.7) 179 (31.6) 192 (26.3)
Post-high school education [n (%)] 221 (58.3) 364 (70.3) 339 (59.8) 472 (64.7)
MULTIVITAMIN USEb
Yes [n (%)] 119 (44.9) 259 (52.4) 210 (38.1) 260 (36.4)
TUMOR HISTOLOGY, CASES
Serous [n (%)] 255 (63.9) 329 (58.1)
Mucinous [n (%)] 11 (2.8) 26 (4.6)
Endometrioid [n (%)] 77 (19.3) 85 (15.0)
Clear cell [n (%)] 25 (6.3) 60 (10.6)
Other [n (%)] 31 (7.8) 66 (11.7)
Counts do not total to 2,233 subjects due to missing data for some variables.
aIn ﬁrst- or second-degree relative.
bAt least four pills per week during the previous year for at least 48months’ duration of lifetime use (Mayo Clinic subjects) or at least three pills per week for at least
48months during the past 60months (Duke University subjects).
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Table 4 | Associationa between haplotypes derived fromATIC variants and ovarian carcinoma with and without stratification by multivitamin
supplement use among 2,233 subjects (Phases 1 and 2), Mayo Clinic, and Duke University.
Haplotypeb Multivitamin non-users Multivitamin users All subjects
Global
haplotype
test P
value
Estimated
haplotype
frequency
OR (95% CI) Global
haplotype
test P
value
Estimated
haplotype
frequency
OR (95% CI) Global
haplotype
test P
value
Estimated
haplotype
frequency
OR (95% CI)
0.56 0.01 0.70
001101000 0.26 1.04 (0.86–1.26) 0.24 0.76 (0.59–0.97) 0.25 0.93 (0.81–1.07)
010000001 0.26 0.98 (0.81–1.19) 0.25 0.82 (0.65–1.04) 0.26 0.94 (0.82–1.08)
100001011 0.05 1.23 (0.84–1.79) 0.05 0.74 (0.46–1.19) 0.05 1.05 (0.80–1.38)
000101000 0.07 1.16 (0.89–1.51) 0.07 0.96 (0.68–1.35) 0.06 1.01 (0.82–1.23)
100010000 0.10 0.73 (0.55–0.98) 0.10 1.10 (0.78–1.55) 0.10 0.95 (0.78–1.16)
101001011 0.01 0.69 (0.29–1.66) 0.02 1.28 (0.53–3.05) 0.01 0.77 (0.42–1.40)
101010000 0.02 1.13 (0.63–2.03) 0.03 1.50 (0.79–2.87) 0.02 1.17 (0.78–1.75)
000000100 0.03 0.87 (0.56–1.38) 0.03 1.52 (0.90–2.56) 0.03 1.02 (0.73–1.43)
001000100 0.13 1.00 (0.78–1.29) 0.13 1.39 (1.04–1.87) 0.13 1.16 (0.97–1.38)
011000001 0.06 1.07 (0.79–1.45) 0.08 1.42 (1.04–1.95) 0.06 1.12 (0.91–1.39)
aAdjusted for age (<40, 40–49, 50–59, 60–69, and 70+ yrs), residence (Minnesota, Iowa,Wisconsin, Illinois, North Dakota, South Dakota, and North Carolina), body
mass index, age at menarche, oral contraceptive use, postmenopausal status, postmenopausal hormone use, parity/age at ﬁrst birth, smoking, and education (see
Table 1 for categories). Haplotype associations were estimated using log-additive logistic regression models.
bEstimated using both cases and controls; SNPs that formed ATIC haplotypes were, in positional order, rs3772078, rs2372536, rs1880586, rs1983462, rs16853826,
rs7586969, rs16853834, rs1404772, rs7604984, where 0= common allele and 1= rare allele. Bold indicates the two signiﬁcant SNPs with opposing effects
from Table 3.
then begin to unravel the functional impact of SNP-by-nutrient
interactions.
ATIC catalyzes the ﬁnal two steps in de novo purine biosynthe-
sis, which is the main source of purine nucleotides (Kondo et al.,
2000; Wolan et al., 2004). The ﬁnal atom of the purine ring is
supplied by folate, producing 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR). Not only can AICAR induce apopto-
sis under certain conditions (Hallstrom et al., 2008), but as the
substrate for ATIC, it can be catabolized to the purine “parent”
nucleotide, inosine monophosphate (IMP), that ultimately gen-
erates two of the four bases, adenine and guanine. The bases are
incorporated into DNA and RNA and also function as impor-
tant sources of energy that drive most biologic reactions (e.g.,
ATP, GTP, UTP, CTP; Rodwell, 2000). Conceivably, ATIC may link
nutrient metabolism vis-à-vis the 1-C transfer pathway to enable
autophagy, which is the cellular catabolic degradation response
to starvation or stress whereby cellular proteins, organelles, and
cytoplasm are engulfed, digested, and recycled to sustain cellular
metabolism (Mathew et al., 2007). For example, amino acid star-
vation is a potent inducer of autophagy (Mizushima, 2007), and
defects in autophagy have been linked to tumorigenesis (Mathew
et al., 2007).
Most individuals do not meet their Dietary Reference Intakes
(DRI) for certain nutrients from foods alone. For example, among
non-supplement users, folate intake (on average, <300μg/day;
Zhang et al., 1999; Feigelson et al., 2003; Kelemen et al., 2004;
Ericson et al., 2007) is less than the DRI (400μg/day). A typical
multivitamin contains a minimum of 400μg of folic acid, thereby
increasing some individuals’ intakes to>600μg/day (Zhang et al.,
1999; Feigelson et al., 2003). Pharmacologic doses of vitamin
intake are hypothesized to be both chemo-preventive and chemo-
progressive, and the mechanism(s) for these alterations may be
related to the presence of existing pre-cancerous lesions, where
vitamins like folate are required for growth by proliferating cells
including tumors (Kim, 2003), and/or genetic susceptibility. Per-
haps the best known example where nutrients inﬂuence gene-
product function is that of high folate levels physically stabilizing,
and thereby rescuing, MTHFR enzyme function in the presence
of the MTHFR C677T SNP (Frosst et al., 1995; Anonymous, 1999;
Guenther et al., 1999). Individuals with this SNP who also have
higher folate intakes have lower risks of CVD (Klerk et al., 2002)
and cancers of the colon (Giovannucci, 2002; Sharp and Little,
2004) than those with the SNP who have lower folate intakes.
Candidate SNP studies and GWAS examining main effect asso-
ciations between SNPs and cancer risk have revealed relatively
few causal variants. Given that some environmental exposures are
known to play a role in the development of cancer (World Cancer
Research Fund/American Institute for Cancer Research, 2007), it
is entirely possible that the genetic effects assumed present but
not yet found may be hidden within speciﬁc subsets of individuals
deﬁned by their environmental exposures, as shown in the current
study. The SNPs in this investigation would not have been iden-
tiﬁed had we only focused on main effects, supporting the need
for more studies such as this one to fully discern the interplay
between genes and environment on risk of cancer. Large inter-
national consortia with well-annotated exposure and phenotype
information, such as the international Ovarian Cancer Associa-
tion Consortium, are well-positioned to provide the large sample
sizes needed to detect effect modiﬁcation, especially for SNPs with
low MAF.
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The strengths of this analysis include the use of stringent quality
control for genotyping that resulted in few excluded or failed sam-
ples, with remaining call rates over 99%, and the large sample to
investigate our ﬁndings for the SNP-by-multivitamin interactions,
especially for ATIC SNPs. Population structure is unlikely, since
analyses were restricted to Caucasians and there was no statisti-
cal heterogeneity in SNP associations between study sites. There
are also potential limitations. For most other SNPs, the power
to detect gene–environment interactions was low. Although we
applied the FDR method to estimate the number of falsely positive
interactions, the application of FDR has been traditionally to high
dimensionality data and may not be applicable to smaller datasets.
Nevertheless, the consistent associations in the combined Phases
1 and 2 sample of two of the six SNPs with lower FDR values from
Phase 1, in addition to the multi-variant and haplotype analyses
of ATIC SNP-by-multivitamin interactions, suggests the associa-
tions may not be due to chance. Another potential limitation is
that we did not have information on dietary intake to verify which
nutrient(s) was related to the modifying effects of multivitamins.
Although self-reported multivitamin supplement use adequately
represents the higher nutrient status among consumers compared
to non-consumers (Zhang et al., 1999, 2003; Kelemen et al., 2004),
the potential for misclassiﬁcation of this exposure may still exist
in our study. The reference period for multivitamin use differed
by site resulting in a slightly different deﬁnition in the Mayo Clinic
and the Duke University studies. Our results for the interaction
P values were somewhat attenuated compared to analyses that
disregarded the information on duration of use (data not shown).
Ostensibly,misclassiﬁcation of exposure, althoughpresent,did not
appear to inﬂuence our ﬁndings substantially.
In summary, this report provides little statistical evidence that
SNPs in ATIC, SHMT2, and SLC46A1 are independently associ-
ated with ovarian carcinoma risk. The statistical interaction of
ATIC SNPs with regular multivitamin intake and ATIC’s role in
cellular metabolism and autophagy may support these ﬁndings as
relevant to ovarian health and disease processes.
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APPENDIX
FIGUREA1 | Linkage disequilibrium plot for tagSNPs inAITC using
2,233 Caucasian subjects, Mayo Clinic, and Duke University. Numbers
in squares indicate the correlation (r 2) between SNPs.
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Table A2 | Characteristics of 1,575 Caucasian subjects (Phase 1), Mayo Clinic, and Duke University.
Mayo Clinic Duke University
Cases (n=312) Controls (n=439) Cases (n=343) Controls (n=481)
Age, years [mean (SD)] 60.8 (12.8) 60.0 (12.9) 56.8 (10.4) 54.6 (12.0)
BODY MASS INDEX, kg/m2
<23 [n (%)] 57 (18.5) 103 (23.7) 96 (29.0) 132 (28.1)
23–26 [n (%)] 77 (24.9) 125 (28.8) 85 (25.7) 117 (25.0)
26–29 [n (%)] 61 (19.7) 88 (20.3) 75 (22.7) 110 (23.5)
≥29 [n (%)] 114 (36.9) 118 (27.2) 75 (22.7) 110 (23.5)
AGEAT MENARCHE, year
<12 [n (%)] 46 (18.5) 67 (15.7) 88 (25.7) 85 (17.7)
12 [n (%)] 60 (24.1) 97 (22.8) 99 (29.0) 142 (29.5)
13 [n (%)] 66 (26.5) 126 (29.6) 82 (24.0) 140 (29.1)
≥14 [n (%)] 77 (30.9) 136 (31.9) 73 (21.4) 114 (23.7)
ORAL CONTRACEPTIVE USE, months
Never [n (%)] 150 (49.7) 166 (38.9) 116 (34.5) 148 (31.0)
1–48 [n (%)] 75 (24.8) 90 (21.1) 105 (31.3) 133 (27.8)
≥48 [n (%)] 77 (25.5) 171 (40.1) 115 (34.2) 197 (41.2)
POSTMENOPAUSAL STATUS
Yes [n (%)] 222 (73.0) 328 (75.1) 251 (80.2) 312 (66.1)
POSTMENOPAUSAL HORMONE USE, months
Never [n (%)] 193 (62.7) 244 (58.5) 108 (33.4) 270 (59.3)
1–60 [n (%)] 54 (17.5) 79 (18.9) 114 (35.3) 96 (21.1)
≥60 [n (%)] 61 (19.8) 94 (22.5) 101 (31.3) 89 (19.6)
PARITY, n/age at first birth, year
Nulliparous [n (%)] 56 (18.0) 64 (14.7) 71 (20.7) 64 (13.3)
1–2/≤20 [n (%)] 20 (6.4) 24 (5.5) 46 (13.4) 57 (11.9)
1–2/≥20 [n (%)] 91 (29.2) 130 (29.9) 125 (36.4) 211 (43.9)
≥3/≤20 [n (%)] 59 (18.9) 63 (14.5) 49 (14.3) 61 (12.7)
≥3/≥20 [n (%)] 86 (27.6) 154 (35.4) 52 (15.2) 88 (18.3)
FAMILY HISTORY OF OVARIAN CANCERa
Yes [n (%)] 41 (13.1) 33 (7.5) 33 (9.6) 26 (5.4)
SMOKING, pack-years
None [n (%)] 194 (65.3) 279 (68.2) 190 (57.8) 250 (54.1)
≤20 [n (%)] 56 (18.9) 82 (20.1) 80 (24.3) 121 (26.2)
>20 [n (%)] 47 (15.8) 48 (11.7) 59 (17.9) 91 (19.7)
EDUCATION
No diploma [n (%)] 18 (6.1) 19 (4.3) 26 (7.6) 42 (8.7)
High School diploma [n (%)] 107 (36.2) 116 (26.5) 105 (30.6) 131 (27.2)
Post-high school education [n (%)] 171 (57.8) 303 (69.2) 212 (61.8) 308 (64.0)
MULTIVITAMIN USEb
Yes [n (%)] 73 (39.9) 217 (51.7) 115 (35.0) 161 (34.6)
TUMOR HISTOLOGY, CASES
Serous [n (%)] 191 (61.2) 206 (60.2)
Mucinous [n (%)] 8 (2.6) 19 (5.7)
Endometrioid [n (%)] 63 (20.2) 53 (15.5)
Clear cell [n (%)] 20 (6.4) 28 (8.2)
Other [n (%)] 30 (9.6) 36 (10.5)
Counts do not total to 1,575 subjects due to missing data for some variables.
aIn ﬁrst- or second-degree relative.
bAt least four pills per week during the previous year for at least 48months’ duration of lifetime use (Mayo Clinic subjects) or at least three pills per week for at least
48months during the past 60months (Duke University subjects).
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Table A4 | Odds ratios (OR) and 95% CIs for the main effect association between variants inATIC, SHMT2, and SLC46A1 and ovarian carcinoma
among 1,575 Caucasian subjects (Phase 1), Mayo Clinic, and Duke University.
Gene/SNP
rsID
Homozygous
major allele
(referent)
Heterozygous Homozygous minor allele P value
(2 df)
Ordinal (per minor allele)
Cases Controls Cases Controls OR (95%CI)a Cases Controls OR (95%CI)a OR (95%CI)a P -trend
ATIC
rs3772078 415 583 201 279 1.0 (0.8–1.3) 20 30 0.9 (0.5–1.7) 0.98 1.0 (0.8–1.2) 0.93
rs2372536 304 409 279 399 1.0 (0.8–1.2) 67 103 0.9 (0.6–1.3) 0.76 0.9 (0.8–1.1) 0.46
rs1880586 167 245 336 473 1.0 (0.8–1.3) 149 201 1.1 (0.8–1.4) 0.88 1.0 (0.9–1.2) 0.61
rs1983462 319 417 275 417 0.9 (0.7–1.1) 60 86 0.9 (0.6–1.3) 0.42 0.9 (0.8–1.1) 0.30
rs16853826 497 696 150 210 1.0 (0.8–1.3) 8 14 0.8 (0.3–2.0) 0.93 1.0 (0.8–1.2) 0.84
rs7586969 259 348 301 436 0.9 (0.7–1.1) 93 134 0.9 (0.7–1.3) 0.76 1.0 (0.8–1.1) 0.55
rs16853834 442 657 187 241 1.1 (0.9–1.4) 26 22 1.7 (0.9–3.1) 0.13 1.2 (1.0–1.4) 0.06
rs1404772 568 807 84 108 1.1 (0.8–1.5) 3 4 1.1 (0.2–5.0) 0.86 1.1 (0.8–1.4) 0.59
rs7604984 242 332 317 442 1.0 (0.8–1.2) 96 144 0.9 (0.7–1.2) 0.84 1.0 (0.8–1.1) 0.64
SHMT2
rs7301155 121 187 153 202 1.2 (0.9–1.6) 37 49 1.2 (0.7–1.9) 0.56 1.1 (0.9–1.4) 0.33
rs2229716 601 838 51 79 0.9 (0.6–1.3) 2 1 2.4 (0.2–27.0) 0.63 0.9 (0.7–1.3) 0.70
SLC46A1
rs9894260 531 768 111 148 1.1 (0.8–1.4) 9 3 5.4 (1.4–20.5) 0.04 1.2 (0.9–1.5) 0.14
rs739439 435 610 191 283 0.9 (0.8–1.2) 26 27 1.3 (0.8–2.3) 0.48 1.0 (0.8–1.2) 0.87
rs2239908 197 270 324 473 0.9 (0.7–1.2) 131 175 1.0 (0.8–1.4) 0.76 1.0 (0.9–1.2) 0.99
rs17719944 534 753 113 157 1.0 (0.8–1.3) 7 9 1.1 (0.4–3.1) 0.96 1.0 (0.8–1.3) 0.81
aAdjusted for age (<40, 40–49, 50–59, 60–69, and 70+ years) and region of residence (Minnesota, Iowa,Wisconsin, Illinois, North Dakota, South Dakota, and North
Carolina).
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Table A5 | Odds ratios (OR) and 95% CIs for the main effect association between variants inATIC, SHMT2, and SLC46A1 and ovarian carcinoma
among 2,233 Caucasian subjects (Phases 1 and 2), Mayo Clinic, and Duke University.
Gene/SNP
rsID
Homozygous
major allele
(referent)
Heterozygous Homozygous minor allele P value
(2 df)
Ordinal (per minor allele)
Cases Controls Cases Controls OR (95%CI)a Cases Controls OR (95%CI)a OR (95%CI)a P -trend
ATIC
rs3772078 623 810 294 384 1.0 (0.8–1.2) 32 43 1.0 (0.6–1.6) 0.98 1.0 (0.8–1.2) 0.85
rs2372536 455 583 399 530 1.0 (0.8–1.2) 109 143 1.0 (0.7–1.3) 0.95 1.0 (0.9–1.1) 0.84
rs1880586 248 348 482 619 1.1 (0.9–1.3) 235 297 1.1 (0.9–1.4) 0.69 1.0 (0.9–1.2) 0.48
rs1983462 463 573 406 559 0.9 (0.8–1.1) 98 133 0.9 (0.7–1.2) 0.54 0.9 (0.8–1.1) 0.32
rs16853826 734 957 220 291 1.0 (0.8–1.2) 14 17 1.1 (0.5–2.3) 0.92 1.0 (0.8–1.2) 0.97
rs7586969 377 469 448 602 0.9 (0.8–1.1) 141 192 0.9 (0.7–1.2) 0.66 0.9 (0.8–1.1) 0.39
rs16853834 665 902 268 328 1.1 (0.9–1.3) 34 33 1.4 (0.8–2.2) 0.32 1.1 (1.0–1.3) 0.15
rs1404772 846 1,107 118 152 1.0 (0.8–1.3) 4 5 1.1 (0.3–4.1) 0.99 1.0 (0.8–1.3) 0.98
rs7604984 367 483 455 577 1.0 (0.9–1.3) 146 202 1.0 (0.7–1.2) 0.75 1.0 (0.9–1.1) 0.87
SHMT2
rs7301155 398 545 404 530 1.0 (0.9–1.3) 86 114 1.0 (0.8–1.4) 0.87 1.0 (0.9–1.2) 0.64
rs2229716 902 1,175 63 86 0.9 (0.7–1.3) 2 2 1.1 (0.1–7.7) 0.92 0.9 (0.7–3.3) 0.73
SLC46A1
rs9894260 799 1,056 152 202 1.0 (0.8–1.2) 13 6 3.1 (1.1–8.3) 0.08 1.1 (0.9–1.3) 0.44
rs739439 627 845 298 281 1.0 (0.9–1.3) 40 39 1.4 (0.9–2.2) 0.36 1.1 (0.9–1.3) 0.25
rs2239908 267 370 495 642 1.1 (0.9–1.3) 203 251 1.1 (0.9–1.4) 0.73 1.1 (0.9–1.2) 0.43
rs17719944 784 1,040 174 211 1.1 (0.9–1.4) 8 13 0.9 (0.4–2.1) 0.66 1.1 (0.9–1.3) 0.53
aAdjusted for age (<40, 40–49, 50–59, 60–69, and 70+ years) and region of residence (Minnesota, Iowa,Wisconsin, Illinois, North Dakota, South Dakota, and North
Carolina).
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